The integration offers early detection, real-time health monitoring, and tailored support to enhance patient outcomes and quality of life
GOQii has joined forces with Acrannolife Genomics, a pioneer in precision diagnostics, to launch the GrafCare Program. The ground-breaking initiative leverages advanced genomic diagnostics, artificial intelligence (AI), and personalised health monitoring to redefine post-transplant care for organ recipients in India.
The GrafCare Program combines Acrannolife’s patented Trunome test with GOQii’s smart health ecosystem. The integration offers early detection, real-time health monitoring, and tailored support to enhance patient outcomes and quality of life.
Key Features of the GrafCare Program
- Early Detection with Trunome Test: Acrannolife’s US-patented Trunome test is a non-invasive blood test identifying early signs of organ rejection or infection. Powered by advanced genomic research and AI, the test provides clinicians with precise, actionable insights to intervene before complications escalate.
- AI-Powered Personalised Health Monitoring: Patients receive a GOQii Smart Vital Device, which tracks vital parameters such as heart rate, blood pressure, and oxygen levels in real-time. AI-driven predictive analytics assess patient data to generate early alerts and personalised recommendations, enabling proactive care.
- Preventive Care and Expert Coaching: The programme provides access to nutritionists and counsellors who design customised recovery plans tailored to each patient’s genetic profile and health data. A focus on preventive care helps patients manage long-term health while reducing reliance on reactive interventions.
- Financial Accessibility: To make advanced care accessible, the programme offers interest-free loans for up to one year, along with discounts on immunosuppressants and free diagnostic tests such as Tacrolimus and kidney/liver function tests.
“This is more than a health programme; it’s a lifeline for transplant recipients,” said Vishal Gondal, Founder and CEO, GOQii. “With GrafCare, we’re harnessing the power of AI and genomics to empower patients and clinicians alike, offering a new level of care that was previously unattainable,” he added.
“Having personally experienced the transplant journey within my own family, I understand the emotional and physical challenges patients face. The GrafCare Program, powered by our US-patented Trunome test, offers early and accurate detection of organ rejection, giving patients the best chance to protect their graft. Our goal is to provide the highest level of care, so transplant recipients can focus on healing and living a full, healthy life without the added worry of their health or finances,” said Agragesh Ramani, Co-founder, Acrannolife Genomics.
